Match!
Stephan Reichenbach Oberarzt
SurgeryRandomized controlled trialPhysical therapyOsteoarthritisMedicine
110Publications
36H-index
7,303Citations
What is this?
Publications 114
Newest
#1Stephan Reichenbach Oberarzt (University of Bern)H-Index: 36
#2David T. Felson (University of Manchester)H-Index: 137
Last. Gillian A. Hawker (U of T: University of Toronto)H-Index: 73
view all 11 authors...
Importance Individually calibrated biomechanical footwear therapy may improve pain and physical function in people with symptomatic knee osteoarthritis, but the benefits of this therapy are unclear. Objective To assess the effect of a biomechanical footwear therapy vs control footwear over 24 weeks of follow-up. Design, Setting, and Participants Randomized clinical trial conducted at a Swiss university hospital. Participants (N = 220) with symptomatic, radiologically confirmed knee osteoarthriti...
Source
Objectives To determine the diagnostic accuracy of clinical tests for cam or pincer morphology in individuals with suspected femoroacetabular impingement (FAI) syndrome and to evaluate their clinical utility. Design A systematic review of studies investigating the diagnostic accuracy of clinical tests for cam and pincer morphology. Data sources PubMed, Embase, CINAHL and SPORTDiscus. Eligibility criteria for selecting studies Studies investigating the diagnostic accuracy of clinical tests for ca...
Source
Discontinuation of denosumab is associated with a rapid return of bone mineral density (BMD) to baseline and an increased risk of multiple vertebral fractures. No subsequent treatment regimen has yet been established for preventing either loss of BMD or multiple vertebral fractures after denosumab discontinuation. The aim of this 8-year observational study was to investigate the effect of a single zoledronate infusion, administered 6 months after the last denosumab injection, on fracture occurre...
4 CitationsSource
#1Sabine Adler (University of Bern)H-Index: 10
#2Stephan Reichenbach Oberarzt (University of Bern)H-Index: 36
Last. Peter M. Villiger (University of Bern)H-Index: 44
view all 6 authors...
OBJECTIVE It is currently unknown how long GCA should be treated with tocilizumab. In the first randomized controlled trial, the biologic agent was stopped after 52 weeks. We therefore studied what proportion of patients relapsed, when relapses occurred and whether factors might predict relapse after tocilizumab treatment discontinuation. METHODS All patients in the tocilizumab arm who had received a 52-week treatment were evaluated. In case of lasting remission, magnetic resonance angiography (...
3 CitationsSource
#1Burkhard MöllerH-Index: 21
#2Philip Bender (University of Bern)H-Index: 3
Last. Kim S. Midwood (University of Oxford)H-Index: 28
view all 12 authors...
1 CitationsSource
#2Martin BeckH-Index: 36
Last. Stephan Reichenbach Oberarzt (University of Bern)H-Index: 36
view all 7 authors...
OBJECTIVES: Increased thickness of subchondral acetabular bone with associated articular cartilage thinning in hips with femoroacetabular (FAI) cam impingement has been observed on magnetic resonance imaging (MRI). Dynamic attrition by the cam deformity moving into the acetabulum may potentiate trans-articular shear stresses thus causing these subchondral bone changes. We aimed to quantify the hypertrophic changes of subchondral acetabular bone in patients with cam-type FAI. METHODS: MRI studies...
Source
#1Andrea D GloorH-Index: 2
#2Daniel YerlyH-Index: 15
Last. Peter M. VilligerH-Index: 44
view all 7 authors...
Objective Tocilizumab is effective in inducing and maintaining remission of GCA. Despite clinical and serological control of disease, magnetic resonance angiography may show persistence of inflammatory signals of unknown significance in arterial walls. Thus, there is an unmet need for tools to detect subclinical disease activity. Methods Immune-inflammatory markers were measured in prospectively collected sera of the first randomized, double-blind, placebo-controlled trial investigating the use ...
9 CitationsSource
#1Eva-Maria Didden (University of Bern)H-Index: 2
#2Yann Ruffieux (University of Bern)H-Index: 1
Last. Matthias Egger (University of Bern)H-Index: 137
view all 10 authors...
BACKGROUND Decision makers often need to assess the real-world effectiveness of new drugs prelaunch, when phase II/III randomized controlled trials (RCTs) but no other data are available. OBJECTIVE To develop a method to predict drug effectiveness prelaunch and to apply it in a case study in rheumatoid arthritis (RA). METHODS The approach 1) identifies a market-approved treatment ( S) currently used in a target population similar to that of the new drug ( N); 2) quantifies the impact of treatmen...
2 CitationsSource
#1Georgia Salanti (University of Bern)H-Index: 53
#2Adriani Nikolakopoulou (University of Bern)H-Index: 10
Last. Matthias Egger (University of Bern)H-Index: 137
view all 7 authors...
Background The important role of network meta-analysis of randomized clinical trials in health technology assessment and guideline development is increasingly recognized. This approach has the potential to obtain conclusive results earlier than with new standalone trials or conventional, pairwise meta-analyses.
4 CitationsSource
#2Sabine AdlerH-Index: 10
Last. Peter M. VilligerH-Index: 44
view all 8 authors...
Objective. To analyse magnetic resonance angiographic (MRA) vessel wall signals from a randomized controlled trial of tocilizumab (TCZ) to treat GCA. Methods. Participants were assigned in a 2:1 ratio to receive either TCZ + glucocorticoids (GCs) or placebo +GC infusions at 4-week intervals for 52 weeks. GCs were started at 1 mg/kg/day, then tapered to 0.1 mg/kg/day at week 12 and thereafter down to zero. Patients with initial positive MRA findings underwent control MRA at weeks 12 and 52. Vesse...
18 CitationsSource
12345678910